These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6883729)

  • 1. Experience with trilostane in the treatment of Cushing's syndrome.
    Dewis P; Anderson DC; Bu'lock DE; Earnshaw R; Kelly WF
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):533-40. PubMed ID: 6883729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant falls of plasma cortisol and ACTH levels in a case of Cushing's disease during treatment with trilostane.
    Nomura K; Demura H; Imaki T; Miyagawa M; Ono M; Yano T; Shizume K
    Acta Endocrinol (Copenh); 1984 Jan; 105(1):93-8. PubMed ID: 6320567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trilostane in the management of Cushing's syndrome.
    Semple CG; Beastall GH; Gray CE; Thomson JA
    Acta Endocrinol (Copenh); 1983 Jan; 102(1):107-10. PubMed ID: 6297208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trilostane for Cushing's syndrome.
    Med Lett Drugs Ther; 1985 Oct; 27(698):87-8. PubMed ID: 4046969
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
    Komanicky P; Spark RF; Melby JC
    J Clin Endocrinol Metab; 1978 Nov; 47(5):1042-51. PubMed ID: 233687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
    Engelhardt D; Weber MM
    J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of trilostane for the treatment of equine Cushing's syndrome.
    McGowan CM; Neiger R
    Equine Vet J; 2003 Jun; 35(4):414-8. PubMed ID: 12880011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of a 3 beta-hydroxysteroid dehydrogenase inhibitor (trilostane) on Cushing's syndrome].
    Nakada T; Ishikawa S; Koike H; Kazama T; Katayama T
    Nihon Hinyokika Gakkai Zasshi; 1985 Jan; 76(1):110-5. PubMed ID: 3859681
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum insulin concentrations in horses with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value.
    McGowan CM; Frost R; Pfeiffer DU; Neiger R
    Equine Vet J; 2004 Apr; 36(3):295-8. PubMed ID: 15147141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of trilostane for Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia.
    Obata Y; Yamada Y; Baden MY; Hosokawa Y; Saisho K; Tamba S; Yamamoto K; Matsuzawa Y
    Intern Med; 2011; 50(21):2621-5. PubMed ID: 22041369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing's syndrome.
    Majnik J; Szücs N; Patócs A; Tóth M; Balogh K; Varga I; Gláz E; Rácz K
    J Endocrinol Invest; 2004 Sep; 27(8):747-53. PubMed ID: 15636428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
    Verhelst JA; Trainer PJ; Howlett TA; Perry L; Rees LH; Grossman AB; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):169-78. PubMed ID: 1657460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cushing's syndrome. Medical treatment of adrenal hypercorticism].
    Bricaire H; Luton JP
    Horm Res; 1980; 13(4-5):317-24. PubMed ID: 7274999
    [No Abstract]   [Full Text] [Related]  

  • 14. [Trilostane therapy in patients with hypercorticism].
    Saito Z; Ando A; Hashiba T; Mikeo T; Takeda J
    Horumon To Rinsho; 1984 Jan; 32(1):53-8. PubMed ID: 6585278
    [No Abstract]   [Full Text] [Related]  

  • 15. A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome.
    al-Saadi N; Diederich S; Oelkers W
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):45-51. PubMed ID: 9509067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary aldosteronism: treatment with trilostane.
    Winterberg B; Vetter W; Groth H; Greminger P; Vetter H
    Cardiology; 1985; 72 Suppl 1():117-21. PubMed ID: 3863713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical Cushing's syndrome in adrenal incidentaloma.
    Terzolo M; Osella G; Alì A; Borretta G; Cesario F; Paccotti P; Angeli A
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):89-97. PubMed ID: 9509073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trilostane and the normal hypothalamic-pituitary-testicular axis.
    Semple CG; Weir SW; Thomson JA; Beastall GH
    Clin Endocrinol (Oxf); 1982 Jul; 17(1):99-102. PubMed ID: 6749342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome.
    Engelhardt D; Jacob K; Doerr HG
    Klin Wochenschr; 1989 Feb; 67(4):241-7. PubMed ID: 2538676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trilostane and the normal hypothalamic-pituitary-adrenocortical axis.
    Semple CG; Thomson JA; Stark AN; McDonald M; Beastall GH
    Clin Endocrinol (Oxf); 1982 Dec; 17(6):569-75. PubMed ID: 6299624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.